Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is poised for success with a unique opportunity in the chronic cough market, supported by its strong IP and differentiated mechanism of action. With the recent discontinuation of GSK's rival therapy, Haduvio now has the potential for broader use beyond later-line treatment and could become a blockbuster drug with a peak sales potential of over $6 billion. Additionally, the company has a focused and efficient strategy with a manageable salesforce, and the upcoming catalysts for the IPF pivotal studies could provide further momentum for the stock. Investors should not overlook the potential for Haduvio in the broader market for RCC, as successful lower-dose data from the ongoing LAKE study could expand its use and significantly increase its addressable market.

Bears say

Trevi Therapeutics is facing M&A speculation due to the highly desirable nature of their asset, Haduvio, and its strong potential for addressing unmet needs in the market, with multiple Phase 2 studies and strong IP. This has led to strong projected financials, with expected revenue and EBITDA growth and increasing margins due to the adoption of Yellow Account and processing margins. These factors warrant a Buy rating with a $85 price target based on a 5.5x 2027E EV/sales multiple and 28x 2027E EV/EBITDA.

TRVI has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 12 analysts, TRVI has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.